Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Hepatic Encephalopathy in Connection With Budd-Chiari Syndrome due to Infection With Echinococcus Multilocularis: A Case Report.

Dulger AC, Kemik O, Selvi F, Begenik H, Emre H, Erdur FM.

Gastroenterology Res. 2011 Jun;4(3):127-130.

2.

Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.

Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R.

Therap Adv Gastroenterol. 2016 Jul;9(4):473-82. doi: 10.1177/1756283X16644249.

3.

Hepatic Encephalopathy: From the Pathogenesis to the New Treatments.

Cordoba J.

ISRN Hepatol. 2014 Jun 4;2014:236268. doi: 10.1155/2014/236268. Review.

4.

Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Ponziani FR, Gerardi V, Pecere S, D'Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A.

World J Gastroenterol. 2015 Nov 21;21(43):12322-33. doi: 10.3748/wjg.v21.i43.12322. Review.

5.

Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

Patidar KR, Bajaj JS.

Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61. doi: 10.1016/j.cgh.2015.06.039. Review.

6.

Management of overt hepatic encephalopathy.

Sharma P, Sharma BC.

J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S82-7. doi: 10.1016/j.jceh.2014.04.004. Review.

7.

Managing complications in cirrhotic patients.

Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D.

United European Gastroenterol J. 2015 Feb;3(1):80-94. doi: 10.1177/2050640614560452.

8.

Sodium benzoate for treatment of hepatic encephalopathy.

Misel ML, Gish RG, Patton H, Mendler M.

Gastroenterol Hepatol (N Y). 2013 Apr;9(4):219-27.

9.

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy.

Kimer N, Krag A, Gluud LL.

Patient Prefer Adherence. 2014 Mar 18;8:331-8. doi: 10.2147/PPA.S41565. Review.

10.

Management of hepatic encephalopathy in the hospital.

Leise MD, Poterucha JJ, Kamath PS, Kim WR.

Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Review.

11.

Rifaximin in the treatment of hepatic encephalopathy.

Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C.

Hepat Med. 2011 Dec 22;3:109-17. doi: 10.2147/HMER.S11988. Review.

12.

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.

Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY.

Gastroenterol Res Pract. 2013;2013:236963. doi: 10.1155/2013/236963.

13.

Update on the management of cirrhosis - focus on cost-effective preventative strategies.

Neff GW, Kemmer N, Duncan C, Alsina A.

Clinicoecon Outcomes Res. 2013 Apr 12;5:143-52. doi: 10.2147/CEOR.S30675.

14.

Antibiotics for the treatment of hepatic encephalopathy.

Patidar KR, Bajaj JS.

Metab Brain Dis. 2013 Jun;28(2):307-12. doi: 10.1007/s11011-013-9383-5. Review.

15.

Rifaximin: recent advances in gastroenterology and hepatology.

Lichtenstein GR.

Gastroenterol Hepatol (N Y). 2007 Jun;3(6):474-83.

16.

Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.

Romeiro FG, da Silva Yamashiro F, Américo MF, Corá LA, Silva GF, Miranda JR, Caramori CA.

BMC Gastroenterol. 2013 Jan 16;13:13. doi: 10.1186/1471-230X-13-13.

17.

Revision and update on clinical practice guideline for liver cirrhosis.

Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver..

Korean J Hepatol. 2012 Mar;18(1):1-21. doi: 10.3350/kjhep.2012.18.1.1. No abstract available.

18.

Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

Eltawil KM, Laryea M, Peltekian K, Molinari M.

World J Gastroenterol. 2012 Feb 28;18(8):767-77. doi: 10.3748/wjg.v18.i8.767. Review.

19.

Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.

Sharma P, Sharma BC.

Saudi J Gastroenterol. 2011 Mar-Apr;17(2):138-41. doi: 10.4103/1319-3767.77246.

20.

PURLs: Another option for patients with liver disease.

Sharma UA.

J Fam Pract. 2010 Sep;59(9):E1-3.

Supplemental Content

Support Center